ArticleBreast cancer research : BCR2025
Multimodal deep learning model for prediction of breast cancer recurrence risk and correlation with oncotype DX.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predictions of Oncotype DXBioengineering (Basel, Switzerland) · 2026Article
- Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes.Journal of cancer research and clinical oncology · 2026Review
- Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundProper stratification of recurrence risk in breast cancer is crucial for guiding treatment decisions. This study aims to predict the recurrence risk of breast cancer patients using a multimodal deep learning model that integrates multiple sequence MRI imaging features with clinicopathologic characteristics.
methodsIn this retrospective study, we enrolled 574 patients with non-metastatic invasive breast cancer from two Chinese institutions between September 2012 and July 2019. We developed a multimodal deep learning (MDL) model by constructing a multi-instance learning framework based on convolutional neural networks. We integrated imaging features from T2WI, DWI, and DCE-MRI sequences with clinicopathologic features for breast cancer recurrence risk stratification. Subsequently, the performance of the MDL model was evaluated using receiver operating characteristic (ROC) curves, the Hosmer-Lemeshow test, calibration curves, and decision curve analysis (DCA). Survival analysis was conducted with Kaplan-Meier survival curves to stratify breast cancer patients into high and low-recurrence risk groups. Time-dependent ROC curves were used to assess 3-year, 5-year, and 7-year recurrence-free survival (RFS) for breast cancer patients. Additionally, we performed differential and enrichment analyses on Oncotype DX genes. We correlated these genes with clinicopathologic features and deep-learning radiographic features using univariate Cox regression and Pearson correlation analysis.
resultsThe MDL model demonstrated good performance in predicting breast cancer recurrence risk and accurately differentiated between high- and low-recurrence risk groups, with an AUC as high as 0.915 (95% CI 0.8448-0.9856). The C-index of prediction models was 0.803 in the testing cohort. The AUCs for 5-year and 7-year RFS were 0.936 (95% CI 0.876-0.997) and 0.956 (95% CI 0.902-1.000) in the validation cohort. In the testing cohort, these AUCs were 0.836 (95% CI 0.763-0.909) and 0.783 (95% CI 0.676-0.891). This study found a significant correlation between Oncotype DX gene expression, clinicopathologic features, and deep-learning radiographic features (p < 0.05).
conclusionsThis study validated the robust predictive accuracy of the MDL model in identifying high- and low-risk groups for recurrence. The correlations identified between Oncotype DX genes, clinicopathologic features, and deep-learning radiographic features offer novel insights for future biomarker research in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.